Pharmaceutical product comprising a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist

Details for Australian Patent Application No. 2009282520 (hide)

Owner AstraZeneca AB Pulmagen Therapeutics (Synergy) Limited

Inventors Avitabile, Barbara Guiseppina; Nadin, Alan John; Ray, Nicholas Charles

Agent Freehills

Pub. Number AU-A-2009282520

PCT Pub. Number WO2010/019098

Priority 0814728.2 12.08.08 GB

Filing date 11 August 2009

Wipo publication date 18 February 2010

International Classifications

C07D 261/08 (2006.01) Heterocyclic compounds having nitrogen and oxygen as the only ring hetero atoms

A61K 31/439 (2006.01) - the ring forming part of a bridged ring system, e.g. quinuclidine

A61P 11/06 (2006.01) Drugs for disorders of the respiratory system

A61P 11/08 (2006.01) Drugs for disorders of the respiratory system

C07D 271/06 (2006.01) Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms

C07D 471/08 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

Event Publications

24 February 2011 PCT application entered the National Phase

  PCT publication WO2010/019098 Priority application(s): WO2010/019098

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009282521-2-hydroxy-ethanesulfonate salt

2009282519-Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient